Joseph F. Hayes, MSc, MBChB; Alexandra Pitman, PhD; Louise Marston, PhD; Kate Walters, PhD; John R. Geddes, MD; Michael King, PhD; David P. J. Osborn, PhD (JAMA Psychiatry. Published online May 11, 2016. doi:10.1001/jamapsychiatry.2016.0432)
Objective To compare rates of self-harm, unintentional injury, and suicide in patients with bipolar disorder who were prescribed lithium, valproate sodium, olanzapine, or quetiapine fumarate.
Design, Setting, and Participants This investigation was a propensity score (PS)–adjusted and PS-matched longitudinal cohort study in a nationally representative UK sample using electronic health records data collected between January 1, 1995, and December 31, 2013. Participants included all patients diagnosed as having bipolar disorder who were prescribed lithium, valproate, olanzapine, or quetiapine as maintenance mood stabilizer treatment.
Main Outcomes and Measures The primary outcome was any form of self-harm. Secondary outcomes were unintentional injury and suicide.
Results Of the 14 396 individuals with a diagnosis of BPD, 6671 were included in the cohort, with 2148 prescribed lithium, 1670 prescribed valproate, 1477 prescribed olanzapine, and 1376 prescribed quetiapine as maintenance mood stabilizer treatment. Self-harm rates were lower in patients prescribed lithium (205; 95% CI, 175-241 per 10 000 person-years at risk [PYAR]) compared with those prescribed valproate (392; 95% CI, 334-460 per 10 000 PYAR), olanzapine (409; 95% CI, 345-483 per 10 000 PYAR), or quetiapine (582; 95% CI, 489-692 per 10 000 PYAR). This association was maintained after PS adjustment (hazard ratio [HR], 1.40; 95% CI, 1.12-1.74 for valproate, olanzapine, or quetiapine vs lithium) and PS matching (HR, 1.51; 95% CI, 1.21-1.88). After PS adjustment, unintentional injury rates were lower for lithium compared with valproate (HR, 1.32; 95% CI, 1.10-1.58) and quetiapine (HR, 1.34; 95% CI, 1.07-1.69) but not olanzapine. The suicide rate in the cohort was 14 (95% CI, 9-21) per 10 000 PYAR. Although this rate was lower in the lithium group than for other treatments, there were too few events to allow accurate estimates.
Conclusions and Relevance Patients taking lithium had reduced self-harm and unintentional injury rates. This finding augments limited trial and smaller observational study results. It supports the hypothesis that lithium use reduces impulsive aggression in addition to stabilizing mood.
To our knowledge, this investigation is the largest naturalistic longitudinal study of fatal and nonfatal self-harm rates in individuals with BPD treated with lithium, valproate, olanzapine, or quetiapine. We found increased rates of self-harm in individuals prescribed valproate, olanzapine, or quetiapine compared with those prescribed lithium. We did not find differences in rates among valproate, olanzapine, and quetiapine. This association remained after PS adjustment and PS matching. We also found reduced rates of unintentional injury in those prescribed lithium, an important association that has not been widely investigated or found previously. We did not find differences in rates of suicide because of the small number of suicides in the cohort. However, the point estimates for rates of suicide among individuals taking lithium or valproate matched those found in the US retrospective cohort study by Goodwin et al
10 (7 per 10 000 PYAR and 17 per 10 000 PYAR, respectively) and are similar to other findings.
11
The lower rates of self-harm in those prescribed lithium may be due either to improved mood stabilization compared with other treatments or specific effects on impulsive aggression and risk taking. The similarity of the negative association between lithium use and unintentional injury and that between lithium use and self-harm supports the latter hypothesis because there is little reason to expect that lower rates of depressive symptoms would reduce unintentional injury.28 Also, there is scant evidence that lithium is superior to quetiapine in preventing depressive episode relapse.7
Our study had notable strengths and limitations. This study uses a large, nationally representative sample to examine rates of fatal and nonfatal self-harm and unintentional injury. The use of EHRs to capture those episodes of self-harm managed entirely in primary care, as well as those admitted to secondary care, captures the true burden of self-harm morbidity both in the community and hospital presentation. Therefore, rates of recorded self-harm in our study were slightly higher than those in previous cohort studies.10,62 As in any analysis of health records, this study would have missed episodes of untreated and unreported self-harm: only population survey methods could capture these episodes, and estimates generated in this manner are prone to response biases. The number of suicides was low, so we were unable to examine differences in rates between drugs. It is possible that misclassification or nonrecording of suicides occurred. However, similarities with other cohorts suggest that this limitation is not a major problem,10,11 and there is no evidence to indicate that misclassification of cause of death would be differential by drug. Exposure time was foreshortened because of both left truncation (eg, practices joining THIN later than 1995) and right censoring (eg, switch to or addition of another drug, patients leaving the primary care practice, or dying of nonsuicide causes). This censoring was equally distributed by exposure drug.
Potential biases relating to selection into the study should have been avoided by the use of contemporaneous, representative medical records, as well as information bias minimized by the use of THIN’s detailed and well-recorded prescribing data as the exposure. However, exposure to the study drug is approximated through prescriptions issued and may not reflect how the patient used the medication. It is possible that erratic adherence is more likely for drugs other than lithium (because lithium is more closely monitored through regular blood tests) and may have contributed to lithium’s perceived superiority. However, these patients had no more physician contacts than those taking other medication, all individuals had to fill more than 1 prescription during their follow-up period (suggesting drug adherence), and other longitudinal cohort studies have not shown differential adherence.63 Because people taking lithium tended to be older, suicides could have occurred in this group before the start of follow-up, thus reducing the observed rate relative to other treatment groups. However, this occurrence should not be the case in the matched analysis.
Through PS adjustment and PS matching, we attempted to account for potential confounding, including confounding by indication, and it is reassuring that both analyses produce similar results. Despite the numerous variables included in the PS, it is possible that residual confounding remained. It may be that important sociodemographic or clinical factors were not captured by the score, and we cannot confirm balance of unobserved covariates.64,65 Notably, detailed information on educational level and individual socioeconomic status is lacking from the database. However, although these covariates are likely to be associated with self-harm, unintentional injury, and suicide, they should not be associated with treatment allocation. For these (or any) unmeasured covariates to have an important effect on the results, they would have to be strongly associated with exposure and outcome and be independent of covariates included in the PS.66,67
Previously, it has been shown that a combination of lithium and valproate was associated with the lowest rate of suicide attempt.16 This group (and other combinations) were excluded from our study because we wanted to examine the association with monotherapy; in fact, treatment with this combination was rare despite recommendations for its use.68
In this representative UK study, individuals with BPD who were prescribed lithium had lower rates of self-harm and unintentional injury than those with BPD receiving other commonly prescribed maintenance treatments. Contrary to the warning from the US Food and Drug Administration,
18 we did not find higher self-harm rates in those prescribed valproate than those receiving other (nonlithium) maintenance drug treatments. These findings are important because they support and augment the existing evidence from randomized clinical trials and smaller cohort studies. Self-harm, unintentional injury, and suicide are important morbidity and mortality outcomes in BPD that appear to be amenable to modification through appropriate drug treatment.
Singhal A, Ross J, Seminog O, Hawton K, Goldacre MJ. Risk of self-harm and suicide in people with specific psychiatric and physical disorders: comparisons between disorders using English national record linkage. J R Soc Med. 2014;107(5):194-204.
Owens D, Horrocks J, House A. Fatal and non-fatal repetition of self-harm: systematic review.
Br J Psychiatry. 2002;181(3):193-199.
PubMed | Link to Article
Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management.
CNS Spectr. 2006;11(6):465-471.
PubMed
Hayes JF, Miles J, Walters K, King M, Osborn DP. A systematic review and meta-analysis of premature mortality in bipolar affective disorder.
Acta Psychiatr Scand. 2015;131(6):417-425.
PubMed | Link to Article
Severus E, Taylor MJ, Sauer C, et al. Lithium for prevention of mood episodes in bipolar disorders: systematic review and meta-analysis.
Int J Bipolar Disord. 2014;2(1):15.
PubMed | Link to Article
Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis.
Lancet Psychiatry. 2014;1(5):351-359.
PubMed | Link to Article
Perlis RH. Hard outcomes: clinical trials to reduce suicide.
Am J Psychiatry. 2011;168(10):1009-1011.
PubMed | Link to Article
Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in
mood disorders: updated systematic review and meta-analysis.
BMJ. 2013;346:f3646.
PubMed | Link to Article
Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex.
JAMA. 2003;290(11):1467-1473.
PubMed | Link to Article
Smith EG, Søndergård L, Lopez AG, Andersen PK, Kessing LV. Association between consistent purchase of anticonvulsants or lithium and suicide risk: a longitudinal cohort study from Denmark, 1995-2001.
J Affect Disord. 2009;117(3):162-167.
PubMed | Link to Article
Baldessarini RJ, Tondo L, Davis P, Pompili M, Goodwin FK, Hennen J. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review [published correction appears in
Bipolar Disord. 2007;9(3):314].
Bipolar Disord. 2006;8(5, pt 2):625-639.
PubMed | Link to Article
Schou M. The effect of prophylactic lithium treatment on mortality and suicidal behavior: a review for clinicians.
J Affect Disord. 1998;50(2-3):253-259.
PubMed | Link to Article
Søndergård L, Lopez AG, Andersen PK, Kessing LV. Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide.
Bipolar Disord. 2008;10(1):87-94.
PubMed | Link to Article
Marangell LB, Dennehy EB, Wisniewski SR, et al. Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD.
J Clin Psychiatry. 2008;69(6):916-922.
PubMed | Link to Article
Ahearn EP, Chen P, Hertzberg M, et al. Suicide attempts in veterans with bipolar disorder during treatment with lithium, divalproex, and atypical antipsychotics.
J Affect Disord. 2013;145(1):77-82.
PubMed | Link to Article
Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder.
J Clin Psychiatry. 2000;61(suppl 9):35-40.
PubMed
US Food and Drug Administration. Suicidal behavior and ideation and antiepileptic drugs.
http://ow.ly/10iLkf. Published May 5, 2009. Accessed April 5, 2016.
Redden L, Pritchett Y, Robieson W, et al. Suicidality and divalproex sodium: analysis of controlled studies in multiple indications.
Ann Gen Psychiatry. 2011;10(1):1.
PubMed | Link to Article
Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs.
N Engl J Med. 2010;363(6):542-551.
PubMed | Link to Article
Leon AC, Solomon DA, Li C, et al. Antiepileptic drugs for bipolar disorder and the risk of suicidal behavior: a 30-year observational study.
Am J Psychiatry. 2012;169(3):285-291.
PubMed | Link to Article
Reid S. Current use of antiepileptic drugs is associated with an increased risk of suicidality in people with depression but not in people with epilepsy or bipolar disorder.
Evid Based Ment Health. 2011;14(1):3.
PubMed | Link to Article
Koek RJ, Yerevanian BI, Mintz J. Subtypes of antipsychotics and suicidal behavior in bipolar disorder.
J Affect Disord. 2012;143(1-3):27-33.
PubMed | Link to Article
Yerevanian BI, Koek RJ, Mintz J. Bipolar pharmacotherapy and suicidal behavior, part 3: impact of antipsychotics.
J Affect Disord. 2007;103(1-3):23-28.
PubMed | Link to Article
Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006.
BMJ. 2011;343:d5422.
PubMed | Link to Article
Matson JL, González ML, Smith KR, Terlonge C, Thorson RT, Dixon DR. Assessing side effects of pharmacotherapy treatment of bipolar disorder: a 20-year review of the literature.
Res Dev Disabil. 2006;27(5):467-500.
PubMed | Link to Article
Elvik R. Risk of road accident associated with the use of drugs: a systematic review and meta-analysis of evidence from epidemiological studies.
Accid Anal Prev. 2013;60:254-267.
PubMed | Link to Article
Khalsa HM, Salvatore P, Hennen J, Baethge C, Tohen M, Baldessarini RJ. Suicidal events and accidents in 216 first-episode bipolar I disorder patients: predictive factors.
J Affect Disord. 2008;106(1-2):179-184.
PubMed | Link to Article
Kovacsics CE, Gottesman II, Gould TD. Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies.
Annu Rev Pharmacol Toxicol. 2009;49:175-198.
PubMed | Link to Article
Fawcett J. Treating impulsivity and anxiety in the suicidal patient.
Ann N Y Acad Sci. 2001;932(1):94-102.
PubMed | Link to Article
Müller-Oerlinghausen B, Lewitzka U. Lithium reduces pathological aggression and suicidality: a mini-review.
Neuropsychobiology. 2010;62(1):43-49.
PubMed | Link to Article
Tondo L, Baldessarini RJ. Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients.
Epidemiol Psichiatr Soc. 2009;18(3):179-183.
PubMed | Link to Article
Blak B, Thompson M, Bourke A. National representativeness and data quality of The Health Improvement Network (THIN) database of primary care information for epidemiological research. Paper presented at: 9th Annual Conference of the UK Federation of Primary Care Research Organisations; November 27, 2006; Liverpool, England.
Blak BT, Thompson M, Dattani H, Bourke A. Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates.
Inform Prim Care. 2011;19(4):251-255.
PubMed
Lis Y, Mann RD. The VAMP Research multi-purpose database in the U.K.
J Clin Epidemiol. 1995;48(3):431-443.
PubMed | Link to Article
Davé S, Petersen I. Creating medical and drug code lists to identify cases in primary care databases.
Pharmacoepidemiol Drug Saf. 2009;18(8):704-707.
PubMed | Link to Article
Health and Social Care Information Centre. Prescriptions Dispensed in the Community, Statistics for England: 2001-2011. Leeds, England: Health and Social Care Information Centre; July 31, 2012.
National Collaborating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents. Leicester, England: British Psychological Society; 2014. NICE Clinical Guidelines CG185.
Nazareth I, King M, Haines A, Rangel L, Myers S. Accuracy of diagnosis of psychosis on general practice computer system.
BMJ. 1993;307(6895):32-34.
PubMed | Link to Article
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review.
Br J Clin Pharmacol. 2010;69(1):4-14.
PubMed | Link to Article
Horsfall L, Walters K, Petersen I. Identifying periods of acceptable computer usage in primary care research databases.
Pharmacoepidemiol Drug Saf. 2013;22(1):64-69.
PubMed | Link to Article
Maguire A, Blak BT, Thompson M. The importance of defining periods of complete mortality reporting for research using automated data from primary care.
Pharmacoepidemiol Drug Saf. 2009;18(1):76-83.
PubMed | Link to Article
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder.
Am J Psychiatry. 1994;151(12)(suppl):1-36.
PubMed | Link to Article
Mok YM, Chan HN, Chee KS, et al; Ministry of Health. Ministry of Health clinical practice guidelines: bipolar disorder.
Singapore Med J. 2011;52(12):914-918.
PubMed
Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.
Bipolar Disord. 2013;15(1):1-44.
PubMed | Link to Article
National Collaborating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children and Adolescents. Leicester, England: British Psychological Society; 2006. NICE Clinical Guidelines CG38.
Lewitzka U, Jabs B, Fülle M, et al. Does lithium reduce acute suicidal ideation and behavior? a protocol for a randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) in patients with suicidal major depressive episode.
BMC Psychiatry. 2015;15(1):117.
PubMed | Link to Article
Baldessarini RJ, Tondo L, Hennen J. Effects of lithium treatment and its discontinuation on suicidal behavior in bipolar manic-depressive disorders.
J Clin Psychiatry. 1999;60(suppl 2):77-84.
PubMed | Link to Article
Haw C, Casey D, Holmes J, Hawton K. Suicidal intent and method of self-harm: a large-scale study of self-harm patients presenting to a general hospital.
Suicide Life Threat Behav. 2015;45(6):732-746.
PubMed | Link to Article
Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score.
J Am Stat Assoc. 1984;79(387):516-524
Link to Article
Holmes WM. Using Propensity Scores in Quasi-Experimental Designs. Thousand Oaks, CA: SAGE Publications; 2013.
Stuart EA. Matching methods for causal inference: a review and a look forward.
Stat Sci. 2010;25(1):1-21.
PubMed | Link to Article
Seeger JD, Kurth T, Walker AM. Use of propensity score technique to account for exposure-related covariates: an example and lesson.
Med Care. 2007;45(10)(suppl 2):S143-S148.
PubMed | Link to Article
Schoenfeld D. Partial residuals for the proportional hazards regression model.
Biometrika. 1982;69(1):239-241.
Link to Article
D’Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.
Stat Med. 1998;17(19):2265-2281.
PubMed | Link to Article
Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39(1):33-38.
StataCorp LP. Stata Statistical Software [computer program]. Release 14. College Station, TX: StataCorp LP; 2015.
Gibbons RD, Hur K, Brown CH, Mann JJ. Relationship between antiepileptic drugs and suicide attempts in patients with bipolar disorder.
Arch Gen Psychiatry. 2009;66(12):1354-1360.
PubMed | Link to Article
Sajatovic M, Valenstein M, Blow F, Ganoczy D, Ignacio R. Treatment adherence with lithium and anticonvulsant medications among patients with bipolar disorder.
Psychiatr Serv. 2007;58(6):855-863.
PubMed | Link to Article
Austin PC, Mamdani MM, Stukel TA, Anderson GM, Tu JV. The use of the propensity score for estimating treatment effects: administrative versus clinical data.
Stat Med. 2005;24(10):1563-1578.
PubMed | Link to Article
Stukel TA, Fisher ES, Wennberg DE, Alter DA, Gottlieb DJ, Vermeulen MJ. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods.
JAMA. 2007;297(3):278-285.
PubMed | Link to Article
Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.
Pharmacoepidemiol Drug Saf. 2006;15(5):291-303.
PubMed | Link to Article
Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies.
J Am Geriatr Soc. 1999;47(6):749-754.
PubMed | Link to Article
Geddes JR, Goodwin GM, Rendell J, et al; BALANCE Investigators and Collaborators. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial.
Lancet. 2010;375(9712):385-395.
PubMed | Link to Article
Leave A Comment